Table II.
Clinical characteristic results of the re-evaluation of the histology of a population-based series of RCC cases from the NLCS 1986-2008, according to the 2022 ISUP grading systems and WHO classification.
| Clinical characteristic | Number (%) |
|---|---|
| Histological reviewa, n (%) | 454 (99.3) |
| Clear cell | 373 (82.2) |
| Papillary | 61 (13.4) |
| Chromophobe | 13 (2.9) |
| Collecting duct carcinoma | 3 (0.7) |
| Oncocytoma | 4 (0.9) |
| Pathologic T stageb, n (%) | 435 (95.8) |
| 1a | 94 (21.6) |
| 1b | 115 (26.4) |
| 2 | 4 (0.9) |
| 2a | 50 (11.5) |
| 2b | 25 (5.7) |
| 3 | 1 (0.2) |
| 3a | 73 (16.8) |
| 3b | 69 (15.9) |
| 4 | 4 (0.9) |
| Sarcomatoid differentiation, n/total (%) | 23/454 (5.1) |
| Rhabdoid differentiation, n/total (%) | 19/454 (4.2) |
| Lymphovascular invasion, n/total (%) | 64/454 (14.1) |
| Necrosis present, n (%) | 152/454 (33.5) |
| Necrosis present per morphotype, n necrosis present/n total cases of the morphotype (%) | |
| ccRCC, n (%) | 111/373 (29.8) |
| pRCC, n (%) | 38/61 (62.3) |
| chRCC, n (%) | 2/13 (15.4) |
| CDC, n (%) | 1/3 (33.3) |
| Oncocytoma, n (%) | 0/4 (0.0) |
| ISUP grade for ccRCC and PRCCc n (%), | 434 (95.6) |
| 1 | 93 (21.4) |
| 2 | 191 (44.0) |
| 3 | 108 (24.9) |
| 4 | 42 (9.7) |
3 scans excluded due to poor quality,
tumor size available for 435 cases. Cases noted as Tumor-Node-Metastasis 2 or 3 which were not further specified as2a, 2b, 3a or 3b, lacked the needed information on tumor size and therefore the original staging information from the cancer registry was used.
ISUP was performed on ccRCC and pRCC cases only. ccRCC, clear cell renal cell carcinoma; CDC, collecting duct carcinoma; ISUP, International Society of Urological Pathologists; NLCS, Netherlands Cohort Study on Diet and Cancer; pRCC, papillary RCC; T stage, tumor stage; WHO, World Health Organization.